{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:21:46Z","timestamp":1793496106799,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.parkreldis.2026.108946","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:25:48Z","timestamp":1787153148000},"page":"108946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative outcomes and healthcare costs of three device-aided pharmacotherapies for patients with advanced Parkinson's disease in Sweden: A nationwide registry-based cohort study"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-7715","authenticated-orcid":false,"given":"Dag","family":"Nyholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Paonessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3437-0267","authenticated-orcid":false,"given":"Filip","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-4580","authenticated-orcid":false,"given":"Jan Erik","family":"Timmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9388-3997","authenticated-orcid":false,"given":"Mikko","family":"Vahteristo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vegard","family":"Lyb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4906-1165","authenticated-orcid":false,"given":"Alexandra","family":"Wennberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2026.108946_bib1","article-title":"Treatment of advanced Parkinson's disease","volume":"2010","author":"Varanese","year":"2011","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2026.108946_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.parkreldis.2022.08.018","article-title":"Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa\/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland","volume":"103","author":"Weiss","year":"2022","journal-title":"Park. Relat. Disord."},{"issue":"13","key":"10.1016\/j.parkreldis.2026.108946_bib3","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.3390\/jcm12134427","article-title":"Levodopa-induced Dyskinesias in arkinson's disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions","volume":"12","author":"di Biase","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108946_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14737175.2023.2176220","article-title":"Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach","volume":"23","author":"Lees","year":"2023","journal-title":"Expert Rev. Neurother."},{"issue":"11","key":"10.1016\/j.parkreldis.2026.108946_bib5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","article-title":"Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty","volume":"130","author":"Auffret","year":"2023","journal-title":"J. Neural Transm."},{"issue":"11","key":"10.1016\/j.parkreldis.2026.108946_bib6","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1002\/mds.28703","article-title":"Levodopa-Carbidopa intestinal gel reduces Dyskinesia in Parkinson's Disease in a randomized trial","volume":"36","author":"Freire-Alvarez","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2026.108946_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2017.02.001","article-title":"Levodopa\/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: an open-label study","volume":"37","author":"Juh\u00e1sz","year":"2017","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2026.108946_bib8","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s00415-023-11615-3","article-title":"Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS","volume":"270","author":"Fasano","year":"2023","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108946_bib9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1877718X241310727","article-title":"Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: results from the phase 3, long-term, open-label United States InfusON study","volume":"15","author":"Isaacson","year":"2025","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108946_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","article-title":"Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease","volume":"64","author":"Nyholm","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108946_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.18773\/austprescr.2025.003","article-title":"Device-assisted therapies for Parkinson disease","volume":"48","author":"Mouchaileh","year":"2025","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.parkreldis.2026.108946_bib12","series-title":"International Review of Neurobiology","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/bs.irn.2017.03.001","article-title":"Chapter sixteen - device-aided treatment strategies in advanced Parkinson's Disease","author":"Timpka","year":"2017"},{"issue":"3","key":"10.1016\/j.parkreldis.2026.108946_bib13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40120-025-00730-0","article-title":"Therapies for advanced Parkinson's Disease in Sweden: a cost-effectiveness analysis using real-world data","volume":"14","author":"Nyholm","year":"2025","journal-title":"Neurol Ther"},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108946_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080720","article-title":"Personalized medicine approach in treating Parkinson's Disease, using oral administration of Levodopa\/Carbidopa microtablets in clinical practice","volume":"11","author":"Gr\u00e9tarsd\u00f3ttir","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.parkreldis.2026.108946_bib15","series-title":"Flexilev Ing\u00e5r i H\u00f6gkostnadsskyddet Med Begr\u00e4nsning, Tandv\u00e5rds- Och L\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV)","year":"2026"},{"key":"10.1016\/j.parkreldis.2026.108946_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CLEP.S282475","article-title":"Adaptation of the charlson comorbidity index for register-based research in Sweden","volume":"13","author":"Ludvigsson","year":"2021","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.parkreldis.2026.108946_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/B978-0-12-804766-8.00014-5","article-title":"Parkinson's disease: diagnosis and appreciation of comorbidities","volume":"167","author":"Deeb","year":"2019","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.parkreldis.2026.108946_bib18","series-title":"WeightIt: Weighting for Covariate Balance in Observational Studies in R_","author":"Greifer","year":"2025"},{"issue":"5","key":"10.1016\/j.parkreldis.2026.108946_bib19","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/10543406.2020.1757692","article-title":"The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring","volume":"30","author":"Dong","year":"2020","journal-title":"J. Biopharm. Stat."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108946_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1468-1331.2009.02866.x","article-title":"Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women","volume":"17","author":"Nyholm","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2026.108946_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WNF.0b013e31825645d1","article-title":"Pharmacokinetics of levodopa\/carbidopa microtablets versus levodopa\/benserazide and levodopa\/carbidopa in healthy volunteers","volume":"35","author":"Nyholm","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108946_bib22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-0404.2012.01700.x","article-title":"Frequent administration of levodopa\/carbidopa microtablets vs levodopa\/carbidopa\/entacapone in healthy volunteers","volume":"127","author":"Nyholm","year":"2013","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.parkreldis.2026.108946_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/ern.13.47","article-title":"Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease","volume":"13","author":"Wright","year":"2013","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108946_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/03009734.2017.1285374","article-title":"Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside","volume":"122","author":"Aquilonius","year":"2017","journal-title":"Upsala J. Med. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108946_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.parkreldis.2026.108946_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1756285616681280","article-title":"Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience","volume":"10","author":"Virhammar","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108946_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3111\/13696998.2014.979937","article-title":"Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany","volume":"18","author":"Walter","year":"2015","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108946_bib28","article-title":"Direct cost of Parkinson's disease: a real-world data Study of second-line therapies","volume":"2020","author":"Gomez-Inhiesto","year":"2020","journal-title":"Parkinsons Dis."},{"issue":"5","key":"10.1016\/j.parkreldis.2026.108946_bib29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40273-022-01132-y","article-title":"The cost effectiveness of levodopa-carbidopa intestinal gel in the treatment of advanced Parkinson's Disease in England","volume":"40","author":"Chaudhuri","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.parkreldis.2026.108946_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.parkreldis.2026.108946_bib31","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3233\/JAD-170572","article-title":"Detection of dementia cases in two Swedish health registers: a validation Study","volume":"61","author":"Rizzuto","year":"2018","journal-title":"J. Alzheimers Dis."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202600773X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202600773X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:34:24Z","timestamp":1791358464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380202600773X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"alternative-id":["S135380202600773X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108946","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative outcomes and healthcare costs of three device-aided pharmacotherapies for patients with advanced Parkinson's disease in Sweden: A nationwide registry-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108946"}}